Epigenetic model may predict who benefits from immunotherapy for stomach and rectal cancers
NCT ID NCT05515796
First seen Apr 12, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This study tested a new way to predict whether immunotherapy before surgery will work for people with stomach or rectal cancer. Researchers used epigenetics (how genes are turned on or off) to build a prediction model. 189 participants were involved, and the goal was to see if the model could accurately forecast a complete response to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Army Medical Center
Chongqing, Other (Non U.s.), 400000, China
Conditions
Explore the condition pages connected to this study.